Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to gre...

Descripción completa

Detalles Bibliográficos
Autores principales: Heller, Simon, Raposo, João Filipe, Tofé, Santiago, Hanif, Wasim, Schroner, Zbynek, Down, Su, Blevins, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/
https://www.ncbi.nlm.nih.gov/pubmed/37092154
http://dx.doi.org/10.2337/cd22-0016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/
https://www.ncbi.nlm.nih.gov/pubmed/37092154
http://dx.doi.org/10.2337/cd22-0016

Ejemplares similares